AstraZeneca says its antibody therapy AZD7442 has failed to achieve its main goal in preventing symptomatic new coronary pneumonia

AstraZeneca (AstraZeneca) Tuesday said Yi item named STORM CHASER after clinical trials failed to provide evidence of its new antibody therapy can protect the crown with the infection who have had people from the effects of the disease, which is looking for its alternative vaccine A small setback in Pin’s efforts
.

The study evaluated whether this combination of two antibodies can prevent adults who have been exposed to the virus in the past eight days from developing symptoms of new coronavirus

Yi item called STORM CHASER after clinical trials failed to provide evidence of its new antibody therapy can protect the crown with the infection who have had people from the effects of the disease, which is its efforts to find a vaccine alternatives in a small setback

AZD7442 was well tolerated in the test
.

Preliminary analysis showed that similar adverse events occurred in the placebo group and the treatment group.

AZD7442 was well tolerated in the test

The AZD7442 therapy is 33% effective in reducing people's risk of symptoms, but the result is not statistically significant

"Although this trial did not meet the primary endpoint for symptomatic diseases, we are encouraged by the protection that PCR-negative participants saw after receiving AZD7442 treatment

Prevent immunization

AZD7442 belongs to a class of drugs called monoclonal antibodies, which mimic the natural antibodies produced by the human body to fight infection
.

It is a combination of two LAABs-tixagevimab (AZD8895) and cilgavimab (AZD1061)-derived from B cells donated by patients recovering from SARS-CoV-2 infection

AZD7442 is currently being tested in several other COVID-19 prevention and treatment trials: PROVENT8 Phase III trial involving more than 5,000 pre-exposure prevention participants; TACKLE COVID-199 Phase III outpatient treatment trial; and collaborators in outpatient and inpatient settings Therapeutic trials conducted in China
.

AZD7442 is being evaluated in IM and intravenous routes of administration

Potently neutralizing and protective human antibodies against SARS-CoV-2

Preliminary "in vitro" findings by researchers at Oxford University and Columbia University also indicate that AZD7442 neutralizes the recently emerged SARS-CoV-2 virus variant
.

Data published in the journal Nature in July 2020 show that in preclinical experiments, LAAB can block the binding of SARS-CoV-2 virus to host cells and prevent infection in cells and animal models of diseases

According to the terms of the license agreement with Vanderbilt, AstraZeneca will pay single-digit royalties based on future net sales
.

Similar therapies developed by competitors Regeneron and Eli Lilly have been approved by U.

European regulators have also approved Regeneron's therapy and are reviewing therapies developed by partners GlaxoSmithKline and Vir Biotechnology, as well as Eli Lilly and Celltrion
.
Regeneron is also seeking US authorization for its use as a preventive treatment
.

But AstraZeneca’s results are a small blow to the pharmaceutical industry as it tries to find more targeted alternatives to new crown vaccination, especially for people who may not be vaccinated or have insufficient response to vaccination
.
It is also developing new treatments and reusing existing drugs to fight the virus
.

But AstraZeneca’s results are a small blow to the pharmaceutical industry as it tries to find more targeted alternatives to new crown vaccination, especially for people who may not be vaccinated or who have insufficiently responded to vaccination
.
But AstraZeneca’s results are a small blow to the pharmaceutical industry as it tries to find more targeted alternatives to new crown vaccination, especially for people who may not be vaccinated or who have insufficiently responded to vaccination
.

AZD7442 is being developed with the support of the US government
.
AstraZeneca announced in March that it had reached an agreement with the US government to provide up to 500,000 doses of AZD7442
.
The company said on Tuesday that it is currently negotiating with the US government on the next steps of the transaction
.
It is negotiating with the US government on the "next step" of a $205 million deal to supply up to 500,000 doses of AZD7442
.
Signed contract with Swiss manufacturer Lonza to produce AZD7442
.

It is negotiating with the US government on the "next step" of a $205 million deal to supply up to 500,000 doses of AZD7442
.
Signed contract with Swiss manufacturer Lonza to produce AZD7442
.
It is negotiating with the US government on the "next step" of a $205 million deal to supply up to 500,000 doses of AZD7442
.
Signed contract with Swiss manufacturer Lonza to produce AZD7442
.

The company said that the complete results will be submitted for publication in a peer-reviewed medical journal
.

Reference materials:

Potently neutralizing and protective human antibodies against SARS-CoV-2, https:// href="https://" target="_blank" rel="noopener">https:// href="https://" target="_blank" rel="noopener">https:// href="https://" target="_blank" rel="noopener">https:// a message here